In Brief: Dade Behring
This article was originally published in The Gray Sheet
Dade Behring: Diagnostic firm broadens its immunosuppressive drug monitoring menu by licensing from Abbott rights to develop a test to monitor for Fujisawa's Prograf FK506 (tacrolimus). Dade Behring initially plans to incorporate the test into its Emit 2000 immunochemistry analyzer. Dade Behring's Emit platform currently includes a test to monitor the levels of cyclosporine in kidney, heart and liver transplant patients. The company also plans to offer for research use an assay to measure in plasma levels of mycophenolic acid (MPA), the active form of Roche's drug CellCept, which is used with FK506 and cyclosporine to prevent organ transplant rejection...
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.